http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#Head
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://www.nanopub.org/nschema#hasAssertion
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://www.nanopub.org/nschema#hasProvenance
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#provenance
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://www.nanopub.org/nschema#hasPublicationInfo
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#pubinfo
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.nanopub.org/nschema#Nanopublication
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion
http://purl.obolibrary.org/obo/DOID_289
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Disease
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#object
http://purl.obolibrary.org/obo/DOID_289
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate
https://w3id.org/biolink/vocab/treats
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#subject
https://identifiers.org/drugbank:DB00014
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
http://www.w3.org/1999/02/22-rdf-syntax-ns#type
http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
http://www.w3.org/2000/01/rdf-schema#label
zoladex is a gonadotropin releasing hormone gnrh agonist indicated for 1 1 1 2 1 3 1 4 1 5 zoladex is indicated for use in combination with flutamide for the management of locally confined stage t2b t4 stage b2 c carcinoma of the prostate treatment with zoladex and flutamide should start 8 weeks prior to initiating radiation therapy and continue during radiation therapy see dosage and administration 2 1 and clinical studies 14 1 zoladex is indicated in the palliative treatment of advanced carcinoma of the prostate see dosage and administration 2 2 clinical studies 14 2 zoladex is indicated for the management of endometriosis including pain relief and reduction of endometriotic lesions for the duration of therapy experience with zoladex for the management of endometriosis has been limited to women 18 years of age and older treated for 6 months see dosage and administration 2 3 clinical studies 14 3 zoladex is indicated for use as an endometrial thinning agent prior to endometrial ablation for dysfunctional uterine bleeding see dosage and administration 2 4 clinical studies 14 4 zoladex is indicated for use in the palliative treatment of advanced breast cancer in pre and perimenopausal women the estrogen and progesterone receptor values may help to predict whether zoladex therapy is likely to be beneficial see dosage and administration 2 6 clinical pharmacology 12 1 clinical studies 14 5 the automatic safety feature of the syringe aids in the prevention of needlestick injury
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
https://w3id.org/biolink/vocab/association_type
https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
https://w3id.org/biolink/vocab/provided_by
https://w3id.org/um/NeuroDKG
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#association
https://w3id.org/biolink/vocab/relation
https://w3id.org/um/neurodkg/SymptomaticReliefIndication
https://identifiers.org/drugbank:DB00014
https://w3id.org/biolink/vocab/category
https://w3id.org/biolink/vocab/Drug
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#provenance
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#assertion
http://www.w3.org/ns/prov#wasAttributedTo
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#pubinfo
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig
http://purl.org/nanopub/x/hasAlgorithm
RSA
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig
http://purl.org/nanopub/x/hasPublicKey
MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig
http://purl.org/nanopub/x/hasSignature
CgDM5Ozx+3KBVVChJ7qUFFYRGdJV7YTmWh3P6tqeTvVffxEp3+ZptZiXvnrHs6+p7hal3FI+LxJe7jGRUARpOetDcbTa5kfU9+b+VZvxIloofaUqasp6hUJ6159l3IaRAjfNQQYuObNIWfwtCaQCcKp+TyjZsocBw86Aub0gyso=
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI#sig
http://purl.org/nanopub/x/hasSignatureTarget
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://purl.org/dc/terms/created
2021-06-30T09:02:23.100+02:00
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
http://purl.org/dc/terms/creator
https://orcid.org/0000-0002-1468-3557
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate
http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate
http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM
http://purl.org/np/RARgQGnPsw2Yi11ld7YAl_oP-yD2pYp4A8Cp5U_F3VgAI
https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate
http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs